Examination of human tumors for rhoA mutations

Jeffrey A. Moscow, Rui He, James R. Gnarra, Turid Knutsen, Yongkai Weng, Wei Peng Zhao, Jacqueline Whang-Peng, W. Marston Linehan, Kenneth H. Cowan

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated rho genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon-or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalOncogene
Volume9
Issue number1
Publication statusPublished - Jan 1 1994
Externally publishedYes

Fingerprint

Mutation
Neoplasms
Tumor Suppressor Genes
Renal Cell Carcinoma
Monomeric GTP-Binding Proteins
Tumor Cell Line
Oncogenes
Open Reading Frames
Transfection
Colon
Carcinogenesis
Breast
Cell Culture Techniques
Fibroblasts
RNA
Phenotype
Cell Line
Lung
Messenger RNA
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Moscow, J. A., He, R., Gnarra, J. R., Knutsen, T., Weng, Y., Zhao, W. P., ... Cowan, K. H. (1994). Examination of human tumors for rhoA mutations. Oncogene, 9(1), 189-194.

Examination of human tumors for rhoA mutations. / Moscow, Jeffrey A.; He, Rui; Gnarra, James R.; Knutsen, Turid; Weng, Yongkai; Zhao, Wei Peng; Whang-Peng, Jacqueline; Linehan, W. Marston; Cowan, Kenneth H.

In: Oncogene, Vol. 9, No. 1, 01.01.1994, p. 189-194.

Research output: Contribution to journalArticle

Moscow, JA, He, R, Gnarra, JR, Knutsen, T, Weng, Y, Zhao, WP, Whang-Peng, J, Linehan, WM & Cowan, KH 1994, 'Examination of human tumors for rhoA mutations', Oncogene, vol. 9, no. 1, pp. 189-194.
Moscow JA, He R, Gnarra JR, Knutsen T, Weng Y, Zhao WP et al. Examination of human tumors for rhoA mutations. Oncogene. 1994 Jan 1;9(1):189-194.
Moscow, Jeffrey A. ; He, Rui ; Gnarra, James R. ; Knutsen, Turid ; Weng, Yongkai ; Zhao, Wei Peng ; Whang-Peng, Jacqueline ; Linehan, W. Marston ; Cowan, Kenneth H. / Examination of human tumors for rhoA mutations. In: Oncogene. 1994 ; Vol. 9, No. 1. pp. 189-194.
@article{f4ebd34153ba47b191a39cd8c173a88a,
title = "Examination of human tumors for rhoA mutations",
abstract = "rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated rho genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon-or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.",
author = "Moscow, {Jeffrey A.} and Rui He and Gnarra, {James R.} and Turid Knutsen and Yongkai Weng and Zhao, {Wei Peng} and Jacqueline Whang-Peng and Linehan, {W. Marston} and Cowan, {Kenneth H.}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "9",
pages = "189--194",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Examination of human tumors for rhoA mutations

AU - Moscow, Jeffrey A.

AU - He, Rui

AU - Gnarra, James R.

AU - Knutsen, Turid

AU - Weng, Yongkai

AU - Zhao, Wei Peng

AU - Whang-Peng, Jacqueline

AU - Linehan, W. Marston

AU - Cowan, Kenneth H.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated rho genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon-or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.

AB - rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated rho genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon-or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.

UR - http://www.scopus.com/inward/record.url?scp=0028107143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028107143&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 189

EP - 194

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 1

ER -